Patrick J. Christmas's most recent trade in Regenxbio Inc was a trade of 4,700 Common Stock done at an average price of $11.2 . Disclosure was reported to the exchange on Feb. 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | Patrick J. Christmas | Chief Strategy & Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.16 per share. | 01 Feb 2026 | 4,700 | 210,667 (0%) | 0% | 11.2 | 52,452 | Common Stock |
| Regenxbio Inc | Patrick J. Christmas | Chief Strategy & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 73,749 | 215,367 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Patrick J. Christmas | Chief Strategy & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 39,650 | 39,650 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Patrick J. Christmas | Chief Strategy & Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.40 per share. | 02 Jan 2026 | 9,793 | 141,618 (0%) | 0% | 14.4 | 141,019 | Common Stock |
| Regenxbio Inc | Patrick J. Christmas | Chief Strategy & Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.19 per share. | 01 Aug 2025 | 4,699 | 151,411 (0%) | 0% | 8.2 | 38,485 | Common Stock |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.07 per share. | 01 Feb 2025 | 4,700 | 156,110 (0%) | 0% | 8.1 | 37,929 | Common Stock |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 223,350 | 223,350 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 02 Jan 2025 | 11,395 | 160,810 (0%) | 0% | 7.7 | 88,083 | Common Stock |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 56,446 | 172,205 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Christmas Patrick J. | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 54,945 | 54,945 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Christmas J. Patrick | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 34,615 | 115,759 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Christmas Patrick J. | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.95 per share. | 02 Jan 2024 | 7,893 | 81,144 (0%) | 0% | 17.9 | 141,679 | Common Stock |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 67,940 | 89,037 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 56,519 | 56,519 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.68 per share. | 03 Jan 2023 | 1,843 | 21,097 (0%) | 0% | 22.7 | 41,799 | Common Stock |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 37,400 | 37,400 | - | - | Stock Option (Right to Buy) | |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 7,900 | 22,940 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.70 per share. | 01 Jan 2022 | 1,332 | 15,040 (0%) | 0% | 32.7 | 43,556 | Common Stock |